EUVIMEDEUVIMED entdecken
Crossref

Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer

Berrin Benli Yavuz, Naile Kökbudak, Gul Kanyilmaz, Meryem Aktan, Mehmet Koc

Clinical and Translational Oncology · 28.07.2026

DOI: 10.1007/s12094-026-04512-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 28.07.2026. Verfasst von Berrin Benli Yavuz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Necmettin Erbakan University Medical School, Konya, Turkey. berrinyavuz77@gmail.com. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lymphovascular space invasion (LVSI) is an established prognostic factor in endometrial cancer; however, its biological and clinical impact in surgically staged early-stage cancer is unclear. This study aimed to evaluate the prognostic significance of substantial LVSI, defined per the WHO 2020 criteria as ≥5 vessel involvement, in stage I-II endometrioid endometrial cancer. METHODS: We retrospectively analyzed 215 patients with surgically staged, lymph-node negative, stage I-II endometrioid endometrial cancer. Substantial LVSI was defined as ≥5 vessel involvement; focal LVSI was classified as negative. Associations between LVSI and clinicopathological features, adjuvant treatment, and survival outcomes were evaluated. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards models for overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS). RESULTS: Substantial LVSI was identified in 6.5% of patients. Substantial LVSI-positive patients received adjuvant radiotherapy more frequently yet demonstrated significantly higher locoregional recurrence. In multivariate analysis, age and stage were independent predictors of OS and DFS; age alone was an independent predictor of DMFS. Substantial LVSI was the only independent prognostic factor for locoregional recurrence (HR: 4.531, 95%Cl 1.453-14.132, p = 0.009). CONCLUSION: Substantial LVSI is a strong predictor of locoregional recurrences in endometrial cancer, even in patients receiving adjuvant radiotherapy. These findings suggest that LVSI reflects an intrinsically aggressive tumor biology that current adjuvant treatment strategies may not fully control.

Schlagwörter

Stichwörter der Autor:innen

Endometrial cancerLocoregional recurrenceRadiotherapySubstantial LVSI

Autor:innen und Institutionen

  • Department of Radiation Oncology, Necmettin Erbakan University Medical School, Konya, Turkey. berrinyavuz77@gmail.com.
  • Department of Medical Pathology, Necmettin Erbakan University Medical School, Konya, Turkey.
  • Department of Radiation Oncology, Necmettin Erbakan University Medical School, Konya, Turkey.

Zitieren

APA

Benli Yavuz, B., Kökbudak, N., Kanyilmaz, G., Aktan, M., & Koc, M. (2026). Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04512-4

Vancouver

Benli Yavuz B, Kökbudak N, Kanyilmaz G, Aktan M, Koc M. Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04512-4

BibTeX
@article{BenliYavuz2026,
  author = {Benli Yavuz, Berrin and Kökbudak, Naile and Kanyilmaz, Gul and Aktan, Meryem and Koc, Mehmet},
  title = {Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04512-4}
}
Kostenlos starten →